Prime Editing Unlocks a Universal Strategy for Restoring Lost Proteins
November 22, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Tofranil, Tofranil-PM
Synonyms :
imipramine
Class :
Antidepressants and antianxiety drugs; norepinephrine reuptake inhibitors
Brand Name :
Tofranil, Tofranil-PM
Synonyms :
imipramine
Class :
Antidepressants and antianxiety drugs; norepinephrine reuptake inhibitors
Dosage forms & Strengths
Tablet
10 mg
25 mg
50 mg
Capsule
75mg
100mg
125mg
150mg
Outpatient:
75
75 orally daily; may be increase up to150 mg/day in divided doses
do not exceed 200 mg a day
Inpatient:
100-150 mg orally daily
may increase up to 200 mg daily
after 2 weeks if there is no response, increase dose up to 250-300 mg
do not exceed 300 mg daily
the Maximum dose given is 50-100 mg orally daily
Dosage forms & Strengths:Â
Tablet
10 mg
25 mg
50 mg
Capsule
75mg
100mg
125mg
150mg
1.5
mg/kg
divided every 8 hours
may increase 1mg/kg every 3-4 days
do not exceed 5 mg/kg
Adolescents:
30-40 mg orally divided 3 times a day
do not exceed 100 mg a day
refer adult dosing
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
imipramine: they may increase the QTc-prolonging effect of QTc-prolonging agents
imipramine: they may increase the QTc-prolonging effect of QTc-prolonging agents
imipramine: they may increase the QTc-prolonging effect of QTc-prolonging agents
imipramine: they may increase the QTc-prolonging effect of QTc-prolonging agents
imipramine: they may increase the QTc-prolonging effect of QTc-prolonging agents
may increase the CNS depressant effect of CNS depressants
may enhance the risk of CNS depression when combined with each other
may enhance the risk of CNS depression when combined with each other
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may have an increased Effect of CNS depressant when combined with serotonergic anorectic drugs
it increases the effect of anticholinergic agents
it increases the toxicity of norepinephrine reuptake inhibitors
it increases the effect of serotonergic agents
Norepinephrine Reuptake Inhibitors increase arrhythmia, causing the effect of dronedarone
anticholinergic agents decrease the efficacy of levosulpride
it increases the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
they increase the effect of Norepinephrine Reuptake Inhibitors
anticholinergic agents increase the ulcer-producing effect of potassium citrate
CNS depressants increase the CNS suppression effect of thalidomide
it increases the effect of Norepinephrine Reuptake Inhibitors
may increase the QT-prolonging effect and enhance the risk of bradycardia, hypokalemia
may increase the serotonergic effect of Monoamine Oxidase Inhibitors
CNS depressants increase the CNS depressing effect of brexanolone
it increases the concentration of Norepinephrine Reuptake Inhibitors
it increases the toxicity of Norepinephrine Reuptake Inhibitors
norepinephrine reuptake inhibitors decrease the effect of guanethidine
it increases the effect of CNS depressants
it increases the toxicity of serotonergic agents
it increases the effect of CNS depressants
anticholinergic agents increase the toxicity of topiramate
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
may have an increased risk of adverse effects when combined with imipramine
may increase the vasopressor effect
It may enhance sedation when combined with a shepherd's purse
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may enhance the cholinergic blocking effect of other tricyclic antidepressants
may enhance the cholinergic blocking effect of other tricyclic antidepressants
may enhance the cholinergic blocking effect of other tricyclic antidepressants
it may diminish the excretion rate when combined with permethrin, resulting in an enhanced serum level
imipramine and dihydroergotamine intranasal are both known to elevate serotonin levels
tricyclic antidepressants: they may increase the toxic effect of Beta2-Agonists
tricyclic antidepressants: they may increase the toxic effect of Beta2-Agonists
tricyclic antidepressants: they may increase the toxic effect of Beta2-Agonists
tricyclic antidepressants: they may increase the toxic effect of Beta2-Agonists
tricyclic antidepressants: they may increase the toxic effect of Beta2-Agonists
The potential for increased CNS depression risk or seriousness occurs when imipramine is used together with pinazepam
when ajmaline is used together with imipramine, the risk or seriousness of QTc prolongation is enhanced
The potential for increased CNS depression risk or seriousness occurs when imipramine is used together with pipecuronium
tricyclic antidepressants: they may increase the toxic effect of Nonsteroidal Anti-Inflammatory Agents
tricyclic antidepressants: they may increase the toxic effect of Nonsteroidal Anti-Inflammatory Agents
tricyclic antidepressants: they may increase the toxic effect of Nonsteroidal Anti-Inflammatory Agents
tricyclic antidepressants: they may increase the toxic effect of Nonsteroidal Anti-Inflammatory Agents
tricyclic antidepressants: they may increase the toxic effect of Nonsteroidal Anti-Inflammatory Agents
when bromazepam and imipramine are used together, there is a potential reduction in the bromazepam's metabolism
The potential for CNS depression may enhanced when imipramine is used together with fencamfamin
may decrease the vasoconstricting effect when combined with alpha-/beta-agonists
When imipramine is used together with niaprazine, the risk or seriousness of CNS depression is enhanced
When dexrabeprazole and imipramine is used together, this leads to reduction in the dexrabeprazole’s metabolism
When imipramine is used together with somatotropin, this leads to a rise in imipramine metabolism
When encainide is used together with imipramine, this leads to a reduction in the encainide’s metabolism
imipramine: they may enhance the serum concentration of CYP2D6 Inhibitors
imipramine: they may enhance the serum concentration of CYP2D6 Inhibitors
imipramine: they may enhance the serum concentration of CYP2D6 Inhibitors
imipramine: they may enhance the serum concentration of CYP2D6 Inhibitors
imipramine: they may enhance the serum concentration of CYP2D6 Inhibitors
When bufexamac is used together with imipramine, this leads to enhanced risk or seriousness of gastrointestinal bleeding
When imipramine is used together with flunoxaprofen, this leads to enhanced risk or seriousness of gastrointestinal bleeding
may have an increased therapeutic effect when combined with alpha1-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
When imipramine is used together with profenamine, this leads to enhanced risk or seriousness of adverse events
when used together, entrectinib and imipramine both increase the QTc interval
may increase the level by affecting the hepatic enzyme CYP3A4 metabolism
it decreases the efficacy of antianxiety agents
may have an increased risk of adverse effects when combined with imipramine
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may enhance the arrhythmogenic effect
may enhance the arrhythmogenic effect
may enhance the arrhythmogenic effect
may enhance the arrhythmogenic effect
may enhance the cholinergic blocking effect of other tricyclic antidepressants
may enhance the cholinergic blocking effect of other tricyclic antidepressants
may enhance the cholinergic blocking effect of other tricyclic antidepressants
may enhance the cholinergic blocking effect of other tricyclic antidepressants
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
the risk of QTc prolongation may be increased
an alteration in the therapeutic activity of either of the drugs may be seen
may enhance the severity of gastrointestinal bleeding when combined
may enhance the severity of gastrointestinal bleeding when combined
may enhance the severity of gastrointestinal bleeding when combined
may enhance the severity of gastrointestinal bleeding when combined
may enhance the severity of gastrointestinal bleeding when combined
ascorbigen, when used in combination with imipramine, the efficacy of imipramine is lowered
When imipramine is aided by hesperetin, it reduces hesperetin’s metabolism
anticholinergic agents increase the effect of constipation of clozapine
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of norepinephrine reuptake inhibitors
anticholinergic agents decrease the efficacy of secretin
CNS depressants increase the effect of zolpidem
Actions and Spectrum:
Antidepressant: Imipramine is primarily used for the treatment of depression. It works by inhibiting the reuptake of neurotransmitters such as serotonin and norepinephrine, leading to increased levels of these chemicals in the brain. By restoring the balance of these neurotransmitters, imipramine helps to alleviate symptoms of depression.
Anxiolytic: Imipramine has anxiolytic properties, meaning it can help reduce anxiety symptoms. It can be used to treat generalized anxiety disorder and certain anxiety disorders such as panic disorder and social anxiety disorder.
Antinociceptive: Imipramine has analgesic properties and can help alleviate pain. It is sometimes used in the treatment of chronic pain conditions, such as neuropathic pain or fibromyalgia. The exact mechanism of its analgesic action is not fully understood.
Enuresis treatment: Imipramine is also used to treat bedwetting (nocturnal enuresis) in children. It can help reduce the frequency of bedwetting episodes by affecting bladder control.
Spectrum of effects: Imipramine affects multiple neurotransmitter systems in the brain, including serotonin, norepinephrine, and acetylcholine. This broad spectrum of action contributes to its antidepressant and anxiolytic effects. However, it also leads to a range of side effects, which should be monitored and managed by a healthcare professional.
Frequency undefined:Â
FatigueÂ
LethargyÂ
SedationÂ
WeaknessÂ
Dry mouthÂ
Blurred visionÂ
AgitationÂ
AnxietyÂ
HeadacheÂ
InsomniaÂ
NauseaÂ
VomitingÂ
SweatingÂ
ECG changesÂ
TachycardiaÂ
ConfusionÂ
Extrapyramidal symptomsÂ
DizzinessÂ
ParesthesisÂ
TinnitusÂ
RashÂ
Increased LFTsÂ
Sexual dysfunctionÂ
SeizureÂ
AgranulocytosisÂ
EosinophiliaÂ
LeukopeniaÂ
ThrombocytopeniaÂ
SIADHÂ
Black Box Warning:
Increased risk of suicidal thoughts and behaviors
Imipramine is contraindicated in patients hypersensitive to the formulation’s active ingredient and other excipients.Â
Pregnancy consideration:Â Â
Imipramine should only be used in pregnant women if the potential benefits outweigh the risk to the fetus.Â
Breastfeeding warnings:Â Â
Use the drug cautiously during lactation, as imipramine is excreted in breast milk.Â
Pregnancy category:Â
Â
Patient information leafletÂ
Generic Name:Â imipramineÂ
Pronounced: im-i-prah-mineÂ
Why do we use imipramine?Â
imipramine is used for several medical conditions. Here are some common uses of imipramine:
imipramine is primarily prescribed for the treatment of depression. It works by increasing the levels of certain neurotransmitters in the brain, such as serotonin and norepinephrine, which helps improve mood and alleviate symptoms of depression.
imipramine is also used in the treatment of nocturnal enuresis, which is bedwetting that occurs during sleep. It can help reduce the frequency of bedwetting episodes by affecting the bladder’s ability to hold urine and improving nighttime bladder control.
imipramine is sometimes prescribed for the treatment of panic disorder and panic attacks. It can help reduce the frequency and severity of panic attacks and alleviate associated symptoms such as palpitations, shortness of breath, and intense fear or anxiety.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
